Bifidobacterium breve for relieving irritable bowel syndrome and application thereof
By using Bifidobacterium breve CCFM1300 to regulate the gut microbiota, the problems of drug side effects and poor treatment efficacy for irritable bowel syndrome (IBS) have been solved. This approach effectively alleviates IBS caused by mother-infant separation stress, reduces pain and bowel frequency, regulates intestinal metabolites, and provides a safe treatment option.
Patent Information
- Application Number
- CN202311365288.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-10-20
- Publication Date
- 2026-03-27
- Estimated Expiration
- 2043-10-20
AI Technical Summary
Existing drugs for treating irritable bowel syndrome (IBS) have problems such as long duration of action and side effects, and there is a lack of effective solutions for IBS caused by mother-infant separation stress.
Using a strain of Bifidobacterium breve CCFM1300, this study reduced the number of fecal particles in individuals with irritable bowel syndrome by regulating the gut microbiota and its metabolites, increased the pain threshold, reduced the number of enterochromaffin cells and colonic 5-HT content, and decreased the relative mRNA expression levels of nerve growth factor and myosin receptor kinase A.
It significantly alleviates irritable bowel syndrome caused by mother-infant separation stress, lowers the visceral pain threshold, reduces the frequency of defecation, reduces the content of 5-HT in the colon, reduces the number of enterochromaffin cells, and reduces the expression of nerve growth factor and myosin receptor kinase A, providing a safe and effective treatment option.